While Roche saw a 1 percent decline in full-year 2024 diagnostics sales year over year, the base business within the division rose 8 percent. Overall, Roche reported ...

Revenues for the three months ended Dec. 31 were $2.62 billion, up from $2.29 billion in Q4 2023 and above the consensus Wall Street estimate of $2.58 billion.

For Q1 2025, Danaher said it expects core revenues will decline in the low-single-digit percent range year over year. For full-year 2025, the company anticipates core revenues will increase ...

Life Sciences revenues rose 3 percent year over year to $7.33 billion from $7.14 billion. Diagnostic revenues increased 2 percent to $9.79 billion from $9.58 billion, while Biotechnology revenues ...

The test, which is intended for assessing cardiovascular risk, is the first lipoprotein (a), or Lp(a) test measured in nanomoles per liter to receive FDA clearance.

The €4.5 million ($4.2 million) effort is led by researchers from Sweden's Karolinska Institute and aims to deliver lateral flow tests and point-of-care devices.

The clinical chemistry test is intended to help diagnose heart failure using the N-terminal pro b-type natriuretic peptide biomarker.

NEW YORK – Medicare administrative contractors Novitas and First Coast Service Options have postponed the implementation dates of two final local coverage determinations that rescinded coverage for ...

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

The molecular test is used to differentiate bacterial infections, viral infections, and noninfectious disease and to assess ...